Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC
Abstract Chemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical outcomes. This prospective study, co...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-024-00781-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595049595011072 |
|---|---|
| author | Masayuki Shirasawa Tatsuya Yoshida Takaji Matsutani Yuki Takeyasu Naoko Goto Shigehiro Yagishita Shigehisa Kitano Hiroaki Kuroda Toyoaki Hida Takayasu Kurata Yuichiro Ohe |
| author_facet | Masayuki Shirasawa Tatsuya Yoshida Takaji Matsutani Yuki Takeyasu Naoko Goto Shigehiro Yagishita Shigehisa Kitano Hiroaki Kuroda Toyoaki Hida Takayasu Kurata Yuichiro Ohe |
| author_sort | Masayuki Shirasawa |
| collection | DOAJ |
| description | Abstract Chemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical outcomes. This prospective study, conducted from November 2019 to May 2021 at three institutions in Japan, evaluated the diversity of TCR repertoire (DE50) in PD-1 + CD8 + T-cells and CD8 + T-cell phenotypes in peripheral blood before and after CRT. Forty patients treated with CRT were included. The diversity and usage of TCR beta variable chains (TRBV) and 14 junctional chains (TRBJ) were significantly and positively correlated before and after CRT. Regarding the DE50, the progression-free survival (PFS) of patients with DE50High before CRT was significantly greater than that of those with DE50Low (NR vs. NR months, HR 0.17, p = 0.01). The diversity of TCR repertoire might more accurately predict the efficacy of CRT followed by durvalumab therapy. |
| format | Article |
| id | doaj-art-6d4210316c384f7197de92140608c06d |
| institution | Kabale University |
| issn | 2397-768X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Precision Oncology |
| spelling | doaj-art-6d4210316c384f7197de92140608c06d2025-01-19T12:08:17ZengNature Portfolionpj Precision Oncology2397-768X2025-01-019111110.1038/s41698-024-00781-wDiversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLCMasayuki Shirasawa0Tatsuya Yoshida1Takaji Matsutani2Yuki Takeyasu3Naoko Goto4Shigehiro Yagishita5Shigehisa Kitano6Hiroaki Kuroda7Toyoaki Hida8Takayasu Kurata9Yuichiro Ohe10Department of Thoracic Oncology, National Cancer Center Hospital, 5‐1‐1 TsukijiDepartment of Thoracic Oncology, National Cancer Center Hospital, 5‐1‐1 TsukijiRepertoire Genesis, Inc, IbarakiDepartment of Thoracic Oncology, National Cancer Center Hospital, 5‐1‐1 TsukijiDepartment of Thoracic Oncology, National Cancer Center Hospital, 5‐1‐1 TsukijiDivision of Molecular Pharmacology, National Cancer Center Research Institute, 5-1-1, TsukijiDivision of Cancer Immunotherapy Development, Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, 3-8-31, AriakeDepartment of Thoracic Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-kuDepartment of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-kuDepartment of Thoracic Oncology, Kansai Medical University Hospital, 2-3-1 ShinmachiDepartment of Thoracic Oncology, National Cancer Center Hospital, 5‐1‐1 TsukijiAbstract Chemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical outcomes. This prospective study, conducted from November 2019 to May 2021 at three institutions in Japan, evaluated the diversity of TCR repertoire (DE50) in PD-1 + CD8 + T-cells and CD8 + T-cell phenotypes in peripheral blood before and after CRT. Forty patients treated with CRT were included. The diversity and usage of TCR beta variable chains (TRBV) and 14 junctional chains (TRBJ) were significantly and positively correlated before and after CRT. Regarding the DE50, the progression-free survival (PFS) of patients with DE50High before CRT was significantly greater than that of those with DE50Low (NR vs. NR months, HR 0.17, p = 0.01). The diversity of TCR repertoire might more accurately predict the efficacy of CRT followed by durvalumab therapy.https://doi.org/10.1038/s41698-024-00781-w |
| spellingShingle | Masayuki Shirasawa Tatsuya Yoshida Takaji Matsutani Yuki Takeyasu Naoko Goto Shigehiro Yagishita Shigehisa Kitano Hiroaki Kuroda Toyoaki Hida Takayasu Kurata Yuichiro Ohe Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC npj Precision Oncology |
| title | Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC |
| title_full | Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC |
| title_fullStr | Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC |
| title_full_unstemmed | Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC |
| title_short | Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC |
| title_sort | diversity of tcr repertoire predicts recurrence after crt followed by durvalumab in patients with nsclc |
| url | https://doi.org/10.1038/s41698-024-00781-w |
| work_keys_str_mv | AT masayukishirasawa diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT tatsuyayoshida diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT takajimatsutani diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT yukitakeyasu diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT naokogoto diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT shigehiroyagishita diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT shigehisakitano diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT hiroakikuroda diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT toyoakihida diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT takayasukurata diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc AT yuichiroohe diversityoftcrrepertoirepredictsrecurrenceaftercrtfollowedbydurvalumabinpatientswithnsclc |